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Abstract Peroxisomal prollferators (HPP), such as ciprofi- 
hrate and clofibric acid, are species-specific drugs. Since HPP- 
coenzyme A derivatives might be involved ln their action, we 
studied the subcellular distribution of liver ciprofibroyl-CoA 
hydrolase in rat and ln two HPP-unresponsive species, humans 
and guinea pig. Total activity was similar ln the three species and 
was not induced by cloflbric acid treatment. In guinea pig, as in 
humans, the enzyme is localized in the mltochondrlal and soluble 
fractions and no changes are observed after drug treatment. In 
the rat, the enzyme has a microsomal localization, but upon 
clotibric acid treatment it changes to a mltochondrlal and soluble 
distribution, as in unresponsive species. These results raise the 
possibility that drug-induced hydrolases in rats might be 
normally expressed in humans and guinea pigs. 
metabolic perturbation that may be induced by the formation 
of the CoASH thioester of HPP in liver cells [14-161. The 
formation of such derivatives has been demonstrated for sev- 
eral HPP [14-191; it is the first event that can be detected after 
drug treatment and results in the rapid depletion of the free 
CoASH content of the liver cell [15,16]. Since the steady-state 
level of HPP-CoAs might be important in determining species 
sensitivity to HPP, we studied the activity and subcellular 
distribution of HPP-CoA hydrolases in rat, human, and gui- 
nea pig liver, using the CoA derivative of ciprofibrate, a very 
active HPP, as substrate. The effect of clofibric acid treatment 
in the behavior of ciprofibroyl-CoA hydrolase was also eval- 
uated in both rat and guinea pig liver. 
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._ 2.1. Materials 
1. Introduction 
Ciprofibrate was kindly provided by Sterling-Winthrop Research 
Institute, NY, USA. Clofibric acid, CoASH, substrates and chemicals 
were purchased from Sigma Chemical Co., St. Louis, MO, USA. 
Peroxisomal proliferation in rats and mice is a well-docu- 
mented phenomenon evoked by a group of diverse com- 
pc unds collectively named hypolipidaemic peroxisomal prolif- 
erators (HPP; recently reviewed in [l]). HPP produce serious 
mi:tabolic perturbations in the liver, and prolonged exposure 
generates hepatocarcinomas in experimental animals [2,3]. 
There are marked differences between species in the peroxiso- 
ma1 proliferation response: e.g. humans and the guinea pig 
ale more resistant than rats and mice [46]. It is thought that 
HPP effects are mediated by a peroxisome proliferator-acti- 
vated (PPAR) receptor [7,8]. Targeted disruption of the 
@PAR isoform gene in mice results in abolishment of 
H PP-induced peroxisomal proliferation [9]. Isoforms of 
PPAR have been described in diverse species including human 
[7.10]. Mouse and human PPAR present a similar tissue dis- 
tnbution. However, the PPAR response toward HPP does not 
completely explain the different sensitivity of humans and 
mice to these xenobiotics [ll]. Thus, other factors besides 
PPAR activation may determine the differential species re- 
sponse to HPP treatment. These factors could be events after 
PPAR activation, in the cross-talk between transcription fac- 
tors inside the nucleus [12,13] or can be related to events prior 
to the formation of ligand-activated PPAR, for instance, the 
2.2. Animals 
Sprague-Dawley rats, weighing 180-200 g, were used. They were 
maintained on a standard laboratory chow diet. For ciprofibrate 
and clofibric acid treatment, rats were fed the same standard chow 
diet containing 30 mg and 3 g of the drug per kg of chow, respec- 
tively. Guinea pigs, weighing l-1.5 kg, were used for experiments. 
They were maintained on a standard rabbit diet, supplemented with 
drug at the same concentration as the rat diet. After 14 days of 
treatment, animals were killed by decapitation and the liver immedi- 
ately processed. 
2.3. Liver biopsies 
Liver biopsies were obtained from patients undergoing surgery for 
uncomplicated gall-stone or gastroduodenal ulcer disease. Informed 
consent from the patients was obtained by following the procedures 
approved by the Ethics Committee of the Medical School of the P. 
Universidad Cat6lica de Chile. 
2.4. Preparation of subcellular fractions 
Tissue homogenates (20%, w/w) were prepared in 0.25 M sucrose 
containing 1 mM dithiothreitol and 3 mM imidazole-HCl, pH 7.4. 
Liver homogenates were fractionated by differential centrifugation 
into nuclear (N), mitochondrial (Mi), microsomal (P) and soluble 
(S) fractions as described [20]. The mitochondrial (Mi) fraction corre- 
sponds to the sum of the classical heavy (M) and light (L) mitochon- 
drial fractions, that are sedimented together [20]. 
2.5. Ciprofibroyl-CoA hydrolase assay 
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Because of interference in the ciprofibroyl-CoA hydrolase spectro- 
photometric assay by a phosphatase capable of degrading ciprofi- 
broyl-CoA to ciprofibroyldephospho-CoA (Urrea and Bronfman, un- 
published results), the enzyme activity was estimated by directly 
measuring the thioester consumed and free drug formed by HPLC. 
Incubations were performed in the presence of phosphate, which in- 
hibits the phosphatase activity. The reaction mixture contained 50 
mM Tris-HCl (pH 8.0), 5 mM KHzPOd (pH 8.0), 120 mM KC1 
and 25-50 FM of the drug-CoA thioester, in a final volume of 50 l.d. 
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The samples were incubated at 35°C and the reaction was stopped by 
the addition of 200 pl of HPLC-grade methanol. After a brief centri- 
fugation, the clear upper phase was used directly for analysis of the 
remaining ciprofibroyl-CoA thioester and the free acid formed. More 
than 95% of the free acid and the drug-CoA thioester was recovered 
under these conditions. HPLC separations were performed on an RP- 
18 (5 mm) column (LichroCart 125-4; Merck, Darmstadt, Germany), 
using as mobile phase 80 mM KHsP04 buffer pH 5.5 containing 48% 
methanol. Under these conditions the retention time of ciprofibrate 
was 4.58 min, and that of ciprofibroyl-CoA 6.9 min. 
2.6. Other assays 
Established procedures described or referenced in [20] were used for 
the determination of protein and marker enzymes: glutamate dehy- 
drogenase for mitochondria; NADPH-cytochrome c reductase for 
microsomal vesicles and fatty acyl-CoA oxidase for peroxisomes. Pal- 
mitoyl-CoA hydrolase was measured spectrophotometrically [20]. 
2.7. Statistics and calculations 
For quantitative evaluation of the subcellular localization of en- 
zymes, we used a computational method based on constrained line- 
ar-regression analysis that has been described and validated previously 
[20,21]. The statistical significance of the assignations was calculated 
by Student’s t-test. 
3. Results 
3.1. Liver activity of ciprojbroyl-CoA and palmitoyl-CoA 
hydrolases 
Table 1 shows the enzyme activities in the liver of control 
and drug-treated animals, and in human liver. No significant 
changes were observed in the liver of guinea pig treated with 
clofibric acid or with the more potent peroxisome proliferator 
ciprofibrate. Rat liver palmitoyl-CoA hydrolase was increased 
upon clofibric acid treatment, in agreement with published 
data [23-251, while fatty acyl-CoA oxidase, a positive control 
of peroxisomal proliferation, was induced Sfold. As for gui- 
nea pigs, no increase in total liver ciprofibroyl-CoA hydrolase 
was observed in drug-treated rats. Rat liver contains M-fold 
more palmitoyl-CoA hydrolase activity than guinea pig or 
human liver. However, no differences were found between 
rat and guinea pig for liver ciprofibroyl-CoA hydrolase activ- 
ity, while human liver contains about half of the rat liver 
activity. 
Fig. 1. Subcellular fractionation of rat and guinea pig liver from 
control and drug-treated animals, and of human liver. Distribution 
of ciprofibroyl-CoA and palmitoyl-CoA hydrolase. For each distri- 
bution pattern, the abscissa represents the protein content of the 
fraction as a percentage of the total protein of the liver. The ordi- 
nate represents the percentage, in the fraction, of the liver content 
of the enzyme divided by the percentage of liver protein in that 
fraction. Recoveries ranged from 89 to 119%. Standardized and 
averaged results [20] from three experiments are presented, except 
for human liver (one experiment). Maximal variation from the 
mean was f 18%. Animals were treated with clofibric acid, as de- 
scribed in Section 2. 
the subcellular distributions of ciprofibroyl-CoA and palmi- 
toyl-CoA hydrolase presented in Fig. 1 were quantified using 
assignation to marker enzymes by constrained linear regres- 
sion [20,21] and are presented in Table 2. 
3.2. Subcellular distribution of hydrolases 
The subcellular distribution of ciprofibroyl-CoA and palmi- 
toyl-CoA hydrolase and that of marker enzymes in rat and 
guinea pig liver from control and drug-treated animals and in 
human liver are shown in Fig. 1. For comparative purposes, 
In control rats ciprofibroyl-CoA hydrolase was present 
mainly in the microsomal fraction, while in drug-treated rats 
most of the activity was present in the cytosol. Quantification 
of these changes (Table 2) show that while the percentage of 
the total enzyme present in the mitochondrial fraction did not 
change upon treatment, the microsomal contribution de- 
creases from 52.1% to 21.4%, and the soluble contribution 
increased from 12.6% to 48.9%. Thus, although in rats the 
absolute value of ciprofibroyl-CoA hydrolase activity, on a 
wet weight liver basis, is not modified by drug treatment, its 
subcellular distribution changes as a consequence of increased 
soluble activity. In an earlier report on the subcellular distri- 
Table 1 
Absolute values of fatty acyl-CoA oxidase and acyl-CoA hydrolase activities 
No. of exneriments Fatty acyl-CoA oxidase Palmitoyl-CoA hydrolase Ciprofibroyl-CoA hydrolase 
Rats 
Control 4 
Clofibric acid treated 4 
0.950 f 0.270 
4.964f 1.7148 
4.410 f 0.460 
6.940 f 1.9508 
0.401 f 0.062 
0.467 f 0.141 
Guinea pigs 
Control 5 0.698 kO.321 0.820 f 0.340 0.487 f 0.140 
Clofibric acid treated 3 0.864 f 0.258 0.780 f 0.270 0.631 f0.169 
Ciprofibrate treated 3 1.088+0.135 0.980 f 0.210 0.633 f0.132 
Human 2 0.169 f 0.023 0.360f0.110 0.155f0.042 
Values of activity refers to 1 g wet wt of liver, and are given in units as means + S.D. The number of independent assays is indicated. 
“Statistically different from control value. 
221 R. Urea, M. BronfmanlFEBS Letters 389 (1996) 219-223 
Table 2 
Assignation by constrained linear regression of ciprofibroyl-CoA and palmitoyl-CoA hydrolases 
- 
Mitochondrial Microsomal Soluble 
R,,t Ciprofibroyl-CoA hydrolase control 26.61+ 8.21 52.llk9.57 12.61 f 7.33 
treated 28.94k4.11 21.35 f 4.498 48,91 k2.81” 
Palmitoyl-CoA hydrolase control 12.03 + 5.01 77.04 + 7.01 7.60 + 5.50 
treated 14.83? 5.06 50.77 f 6.01a 36.40 + 3.75a 
G linea pig Ciprofibroyl-CoA hydrolase control 58.86 + 4.54 13.40 f4.73 22.98 f 3.18 
treated 51.78k5.15 18.06 f 6.76 29.14f 3.86 
Palmitoyl-CoA hydrolase control 7.38 ? 4.60 49.63 + 5.03 38.78 + 3.46 
treated 10.26 f 5.42 59.40 f 6.49 32.37 * 5.64 
H lman Ciprofibroyl-CoA hydrolase 58.20 + 7.79 13.62 f 5.24 25.37 + 4.28 
Palmitoyl-CoA hydrolase 21.45f9.51 51.23 t 6.41 23.92 + 5.23 
Glutamate dehydrogenase and NADPH-cytochrome c reductase were used as marker enzymes of mitochondria and microsomes, respectively. A 
h> pathetical enzyme with 100% of its activity in the soluble compartment was used as marker of the cytosol for the calculations. Results are given 
in percentages ( f SD.) and correspond to analysis of the data shown in Fig. 1. 
“Statistically different from control value. 
bittion of clofibroyl-CoA hydrolase in rat liver, more than 
7%% of the enzyme was found to be present in the soluble 
compartment in both control and clofibrate-treated rats [22]. 
II contrast with our results, no activity was observed by the 
latter authors in the microsomal fraction. Differences between 
our HPLC-based assay and the spectrophotometric assay used 
b!c these authors, or between the HPP-CoA used, might be 
responsible for these differences. In our hands, the activity of 
the microsomal hydrolase was similar when using ciprofi- 
bloyl-CoA, nafenopin-CoA or tibryl-CoA as substrate (not 
sl own). 
No changes in the subcellular distribution of ciprofibroyl- 
CJA hydrolase were observed in the liver of treated guinea 
pigs when compared to that of control animals. A minor 
amount of ciprofibroyl-CoA hydrolase was found in the mi- 
crosomal fraction while most of the activity was in the mito- 
cllondrial (58.8%) and soluble fractions (29.1%). In fact, in the 
unresponsive species, the intracellular distribution of ciprofi- 
b1 oyl-CoA hydrolase resembles better the enzyme localization 
pitttern observed in clofibric acid-treated rats rather than that 
observed in normal rat liver. On the other hand, ciprofibroyl- 
C oA and palmitoyl-CoA hydrolases presented a very different 
distribution in HPP-unresponsive species, while in control rats 
bc)th enzymes present a similar microsomal distribution. 
In agreement with previous data [22,23], soluble palmitoyl- 
CoA hydrolase was increased in drug-treated rats. No changes 
were observed in the distribution of the enzyme in the liver of 
clofibric acid-treated guinea pigs. As for ciprofibroyl-CoA hy- 
drolase, it is noteworthy that the intracellular distribution of 
pahnitoyl-CoA hydrolase in guinea pig and human liver is 
different from that of control rats but similar to the distribu- 
tion of the enzyme in the liver of clofibric acid-treated rats. 
From the data in Tables 1 and 2, the absolute value of the 
enzyme activities in each subcellular fraction can be estimated 
and compared (Table 3). In the rat, palmitoyl-CoA hydrolase 
is increased in the mitochondrial and soluble fractions, con- 
firming earlier observations [23-251, while ciprofibroyl-CoA 
hydrolase is increased mainly in the soluble fraction. It is 
noteworthy that in the guinea pig absolute ciprofibroyl-CoA 
hydrolase activity in the soluble and mitochondrial fractions is 
2-fold higher than the corresponding fractions in the control 
rat, while the reverse is true for the microsomal activity. Thus, 
in untreated animals, the subcellular capacity for destroying 
ciprofibroyl-CoA is totally different in the guinea pig or in the 
rat according to the subcellular compartment involved. 
4. Discussion 
We have previously proposed that the coenzyme A thioe- 
sters of HPP might be the common pharmacologically active 
T ible 3 
A xolute values of ciprofibroyl-CoA and palmitoyl-CoA hydrolase activities in subcellular compartments _ 
Mitochondria Microsomes Soluble 
R its 
( Xprofibroyl-CoA hydrolase control 0.107f0.016 0.209 f 0.032 0.051 f 0.008 
treated 0.135 +0.041 0.100t0.03 0.228 + 0.069 
I’ahnitoyl-CoA hydrolase control 0.531 f 0.055 3.397 f 0.354 0.335 + 0.035 
treated 1.029 f 0.289 3.523 f 0.990 2.526 f 0.710 
Gainea pig 
( Xprofibroyl-CoA hydrolase 0.287 + 0.092 0.065 f 0.019 0.112f0.032 
I’almitoyl-CoA hydrolase 0.061 f 0.025 0.407 + 0.169 0.318+0.132 
V,dues are given in units per g wet wt of liver, as mean & S.D., and were calculated from the total activity in the liver (Table 1) multiplied by the 
percent of activity in each compartment (Table 2). In the case of the guinea pig, only control values are presented, since there was no effect of the 
treatment upon total enzyme activity. 
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metabolite that unifies the structural diversity of these com- 
pounds [1416]. Most HPP present a carboxylic acid func- 
tional group, or a group that can be readily oxidized to car- 
boxylic acid and activated to a CoASH thioester. Even in 
HPP, lacking a carboxylic function as azole compounds, car- 
boxylic groups can arise from metabolic degradation [26]. 
HPP-CoA has been shown to activate protein kinase C 
[27,28], to bind specifically to rat liver cytosolic proteins 
[29], to inhibit acetyl-CoA carboxylase [30] and to modify 
the phosphorylation status of proteins [31]. In this report, 
we investigated the possible existence of differences in the 
degradation of ciprofibroyl-CoA in rat liver and in the liver 
of two HPP non-responsive species, humans and the guinea 
pig. 
Striking differences were found between the rat and the 
HPP-non responsive species in the subcellular distribution of 
ciprofibroyl-CoA and palmitoyl-CoA hydrolase and in the 
response to clofibric acid treatment. In the rat the activity 
of palmitoyl-CoA hydrolase is S-6-fold higher than in the 
unresponsive species. In agreement with published data [23- 
25] it is increased in clofibric acid treated animals, while no 
effect is observed in the guinea pig. In contrast, similar liver 
absolute activities were observed for ciprofibroyl-CoA hydro- 
lase in the three species. In the guinea pig, the enzyme is not 
sensitive to clofibric acid or ciprofibrate treatment. However, 
its distribution pattern, as the human enzyme, shows a rela- 
tively high activity in the mitochondrial and soluble fractions, 
when compared with the rat. This intracellular distribution 
follows the pattern of ciprofibroyl-CoA hydrolase in drug- 
treated rats, which show increased soluble and mitochondrial 
activities when compared to controls. Since, in the rat, HPP 
treatment has been shown to induce cytosolic and mitochon- 
drial long chain acyl-CoA hydrolases which are only weakly 
expressed, if at all, under normal conditions [25], it is tempt- 
ing to speculate that the clofibric acid-inducible ciprofibroyl- 
CoA hydrolase from rat liver is being normally expressed in 
the liver of the guinea pig and other HPP non-responsive 
species, resulting in a more effective degradation of HPP- 
CoAs. 
Whether or not the greater mitochondrial and cytosolic 
capacity of ciprofibroyl-CoA degradation of the liver guinea 
pig can be extended to other HPP-CoAs, or be related with 
the lack of HPP-induced peroxisomal proliferation of this 
species remains to be established. On the other hand, the 
true subcellular localization of the enzyme in the mitochon- 
drial fraction also remains to be established, since our fractio- 
nation method does not discriminate between peroxisomal 
and mitochondrial contributions to enzyme activity in that 
fraction. 
If HPP-CoAs are indeed involved in HPP-induced pleiotro- 
pit effects, other factors such as the liver activity of HPP-CoA 
synthetase may be also involved. Human liver forms ciprofi- 
broyl-CoA at a rate comparable to that of the rat [15], while 
the guinea pig liver is as active as the rat organ in the activa- 
tion of ciprofibrate (Urrea and Bronfman, unpublished re- 
sults). In the rat, long chain mitochondrial and microsomal 
acyl-CoA synthetases have been shown to activate HPP 
[14,15]. In addition to these acyl-CoA synthetases, separate 
microsomal xenobiotic-CoA synthetases exist [32], and also 
a peroxisomal nafenopin-CoA synthetase has been demon- 
strated [33]. The problem is further complicated by the fact 
that acyl-CoA synthetases present different affinities for HPP 
which results in very different intracellular concentrations of 
HPP-CoAs [15], and by the recent report of liver HPP-CoA 
binding proteins with different affinities for HPP-CoAs [29], 
which may also be involved in their effects. Further research 
on species-comparative evaluation of the intracellular concen- 
tration and distribution of HPP-CoAs in vivo, and on the 
liver activity and subcellular distribution of HPP-CoA synthe- 
tases and hydrolases might help us to establish whether or not 
metabolic differences are responsible for the existence of HPP 
responsive and unresponsive species. 
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